Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

BonprixUltimateGuardians May. 13 at 9:17 PM

$MSS $CUE $ISPC $TOUR $KUST like

0 · Reply

BARNABYY May. 13 at 3:26 PM

$CUE so far bears have made nothing

1 · Reply

SirDuncan May. 12 at 12:00 AM

$CUE https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution?utm_medium=web

2 · Reply

BARNABYY May. 11 at 6:45 PM

$CUE load da boat

0 · Reply

SirDuncan May. 11 at 4:06 PM

$CUE https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution?utm_campaign=post&utm_medium=web @tealeaves @Jwhig @TotalAmateur

0 · Reply

Easteregg May. 11 at 3:06 PM

$CUE Rekt.

0 · Reply

tealeaves May. 10 at 5:35 PM

$CUE darn good month. Hoping this consolidates closer to $20 so I can buy more back before the next leg up. Potential catalysts later this summer…

1 · Reply

OnlyFibs May. 9 at 11:30 PM

$CUE monthly chart just printed the biggest green candle in its history off the all-time low. Cue Biopharma — anti-IgE antibody play, new CEO who took her last company public at $2B+, $30M PIPE closed, $676.5M in potential milestones. July 1 Phase 2b decision is the binary. Oh and 278% of the float is short. 🐂 $42–$44 — monthly orange resistance clears, next stops $56 then $71 🐻 $27 — PIPE price zone, lose it and the squeeze thesis resets ⚠️ 278% of float short with a hard catalyst on July 1. If the data is positive this becomes one of the most violent squeezes in biotech this year. Size for the volatility. #CUE #CueBiopharma #ShortSqueeze #IgE #Biotech #hovdid

0 · Reply

NorthernMonkey1 May. 9 at 5:45 PM

$CXAI My 80% research and 20% hopium says earning reports on the 15th, depending on partnerships and contracts announced within this time frame naturally can take this to its SP target. Then factor in bull runs and further catalysts. Hitting two dollars is achievable. From .14 -> 2. Is around a 1,329% increase $CUE $AMD $RXT $ROLR

0 · Reply

BARNABYY May. 9 at 1:52 PM

$CUE

0 · Reply

Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-04T17:37:20.000Z - 9 days ago

Cue Biopharma trading resumes

2026-05-04T17:31:09.000Z - 9 days ago

Cue Biopharma trading halted, volatility trading pause

2026-05-01T12:53:12.000Z - 12 days ago

Why Is Cue Biopharma Stock Up Today?

2026-04-30T21:13:55.000Z - 13 days ago

Cue Biopharma appoints Shao-Lee Lin as CEO

2026-04-30T21:04:54.000Z - 13 days ago

Cue Biopharma announces $30M private placement

Apr 30, 2026, 4:25 PM EDT - 13 days ago

Cue Biopharma Announces $30 Million Private Placement

Apr 30, 2026, 4:15 PM EDT - 13 days ago

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Apr 30, 2026, 4:05 PM EDT - 13 days ago

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

2026-04-28T13:54:10.000Z - 15 days ago

Cue Biopharma trading halted, volatility trading pause

2026-04-28T13:48:36.000Z - 15 days ago

Cue Biopharma trading resumes

2026-04-27T14:37:18.000Z - 16 days ago

Cue Biopharma trading resumes

2026-04-27T13:47:34.000Z - 16 days ago

Cue Biopharma trading halted, volatility trading pause

2026-04-24T13:48:28.000Z - 19 days ago

Cue Biopharma trading resumes

2026-04-24T13:37:14.000Z - 19 days ago

Cue Biopharma trading halted, volatility trading pause

2026-04-23T23:50:37.000Z - 19 days ago

Cue Biopharma trading halted, news pending

2026-04-22T14:15:23.000Z - 21 days ago

Cue Biopharma announces 1-for-30 reverse stock split

Apr 22, 2026, 8:37 AM EDT - 21 days ago

Cue Biopharma Announces 1-for-30 Reverse Stock Split

Apr 13, 2026, 9:00 AM EDT - 4 weeks ago

Cue Biopharma Transcript: AGM 2026

2026-04-08T12:15:20.000Z - 5 weeks ago

Cue Biopharma to receive $7.5M milestone payment from Boehringer Ingelheim pact

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Apr 7, 2026, 10:00 AM EDT - 5 weeks ago

Cue Biopharma Transcript: R&D Day 2026

2026-03-27T20:12:31.000Z - 6 weeks ago

Cue Biopharma CEO Usman Azam steps down

Mar 27, 2026, 4:05 PM EDT - 6 weeks ago

Cue Biopharma Announces CEO Transition

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

2026-03-17T15:35:34.000Z - 2 months ago

Cue Biopharma files $300M mixed securities shelf

Mar 16, 2026, 4:05 PM EDT - 2 months ago

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

2026-03-09T12:20:19.000Z - 2 months ago

Cue Biopharma to present new in vitro data for CUE-401

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

2026-02-17T13:15:58.000Z - 3 months ago

Cue Biopharma announces preclinical safety, tolerability data for CUE-401

Feb 17, 2026, 8:00 AM EST - 3 months ago

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

2026-02-12T13:15:49.000Z - 3 months ago

Cue Biopharma appoints Warren as chief financial and business officer

Feb 12, 2026, 8:00 AM EST - 3 months ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

Dec 19, 2025, 8:00 AM EST - 5 months ago

Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 4:02 PM EST - 5 months ago

Cue Biopharma Announces Proposed Public Offering

Nov 12, 2025, 4:05 PM EST - 6 months ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 8:00 AM EST - 6 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 8 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Sep 5, 2025, 8:00 AM EDT - 8 months ago

Cue Biopharma Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 8:00 AM EDT - 9 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 9 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 11 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 11 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 15, 2025, 11:00 AM EDT - 1 year ago

Cue Biopharma Transcript: Status Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 1 year ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 1 year ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 4:30 PM EDT - 1 year ago

Cue Biopharma Transcript: Status Update

Apr 15, 2025, 2:00 AM EDT - 1 year ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:02 PM EDT - 1 year ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Dec 4, 2024, 9:00 AM EST - 1 year ago

Cue Biopharma Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:15 PM EST - 1 year ago

Cue Biopharma Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 4:30 PM EDT - 1 year ago

Cue Biopharma Earnings Call Transcript: Q2 2024

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 6, 2024, 2:00 PM EDT - 2 years ago

Cue Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

May 14, 2024, 12:00 PM EDT - 2 years ago

Cue Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 2 years ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Cue Biopharma Earnings Call Transcript: Q4 2023

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 2 years ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Feb 13, 2024, 9:20 AM EST - 2 years ago

Cue Biopharma Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Nov 29, 2023, 4:00 PM EST - 2 years ago

Cue Biopharma Transcript: The Piper Sandler 35th Annual Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 9, 2023, 4:30 PM EST - 2 years ago

Cue Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 4:30 PM EDT - 3 years ago

Cue Biopharma Earnings Call Transcript: Q2 2023

Aug 9, 2023, 4:10 PM EDT - 3 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

BonprixUltimateGuardians May. 13 at 9:17 PM

$MSS $CUE $ISPC $TOUR $KUST like

0 · Reply

BARNABYY May. 13 at 3:26 PM

$CUE so far bears have made nothing

1 · Reply

SirDuncan May. 12 at 12:00 AM

$CUE https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution?utm_medium=web

2 · Reply

BARNABYY May. 11 at 6:45 PM

$CUE load da boat

0 · Reply

SirDuncan May. 11 at 4:06 PM

$CUE https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution?utm_campaign=post&utm_medium=web @tealeaves @Jwhig @TotalAmateur

0 · Reply

Easteregg May. 11 at 3:06 PM

$CUE Rekt.

0 · Reply

tealeaves May. 10 at 5:35 PM

$CUE darn good month. Hoping this consolidates closer to $20 so I can buy more back before the next leg up. Potential catalysts later this summer…

1 · Reply

OnlyFibs May. 9 at 11:30 PM

0 · Reply

NorthernMonkey1 May. 9 at 5:45 PM

0 · Reply

BARNABYY May. 9 at 1:52 PM

$CUE

0 · Reply

MorganHoratio May. 8 at 3:11 PM

$CUE: +5.2%, bullish. New CEO & talent grants lifting sentiment, hold. $SOBR: +74.8%, parabolic. Driven by policy/order hype, take profit. $LABT: +28.9%, rebounding. Strong post-IPO bounce from lows, buy small. $ESPR: -0.3%, consolidating. Neutral reaction to recent data, wait. $WTO: -1.1%, bearish. Dilution pressure from offering persists, reduce. Small-caps are delivering pure adrenaline today! $SOBR’s 74% "vertical takeoff" is a textbook momentum play—hope you took profits! Meanwhile, $CUE is showing real strength following its CEO shake-up and fresh capital injection, marking it as a top turnaround candidate to watch. On the flip side, $WTO is still drowning in dilution, a stark reminder that share structure is king in this tier. Do you prefer hunting for the next parabolic runner like $SOBR, or are you betting on a structural recovery like $CUE? What’s your play for the weekend?

1 · Reply

AveraveJoeTrader May. 8 at 2:38 PM

$GOAI Why do I like this company so much? $CUE and $AIOS might want to take some of your profits here..👇🏻👇🏻👇🏻 https://x.com/autumnsdad1/status/2052754476491022786?s=61

0 · Reply

Kesiya May. 8 at 10:03 AM

$GDC Hold on, friends Our target is 117%-200%+. /Watchlist $EZGO $CUE $CTNT $AIIO

0 · Reply

InTheMoney_ May. 8 at 4:33 AM

$SPY $QQQ —> $CUE borrow rate is staying elevated and spiked higher to 380% today. Short sellers are betting the share price will go back down http://finshort.com/CUE/cost-to-borrow

0 · Reply

SmartMoneyTradez May. 8 at 1:50 AM

$CUE consolidating

0 · Reply

focafoca99 May. 7 at 11:26 PM

$CUE awarded inducement equity grants to seven new hires, including CEO Shao‑Lee Lin, under Nasdaq Rule 5635(c)(4).

0 · Reply

BARNABYY May. 7 at 10:09 PM

$CUE 50?

0 · Reply

PeePeePantsCity May. 7 at 6:47 PM

$CUE Longs need to get a CLUE on CUE🤣🤣🤣You can't fix a terrible trader, but you can use duct tape on his fingers to prevent him from executing a bad trade🤣🤣🤣

1 · Reply

PeePeePantsCity May. 7 at 2:28 PM

$CUE 🤣🤣🤣THAT IS ALL..PFT!

0 · Reply

Wolverineone May. 7 at 1:37 PM

$CUE low volume but still starting the day with a nose dive, needs some big buy orders

0 · Reply

Pennytwits May. 7 at 9:16 AM

$CUE they did this yeserday - nobody selling ! the bid will walk back up to $38

2 · Reply

PeePeePantsCity May. 7 at 3:27 AM

$CUE Dam, 5 buck spread...hit that BID🤣🤣🤣

0 · Reply

Market Cap	101.46M
Revenue (ttm)	27.47M
Net Income (ttm)	-26.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-96.83%
Debt to Equity Ratio	0.00

Volume	132,943
Avg Vol	915,352
Day's Range	N/A - N/A
Shares Out	3.24M
Stochastic %K	57%
Beta	2.37
Analysts	Strong Sell
Price Target	$98.39